[Hinews] Xafty, a broad-spectrum antiviral candidate from South Korea’s Hyundaibioscience, has secured an official invitation to present its clinical findings and development roadmap at the Rapid Response Partnership Vehicle (RRPV) annual meeting, convened by U.S. health authorities on August 26-27 in Washington, D.C.

This invitation goes beyond a routine presentation—it signals formal recognition from a U.S. health authority consortium and has drawn global attention. The RRPV program, aimed at addressing public health emergencies like pandemics, supports technology showcases, project alignment, and accelerated evaluations.

The timing is significant: the U.S. Department of Health and Human Services (HHS) recently scaled back or terminated 22 mRNA-based vaccine projects, underscoring the limitations of vaccine-only strategies. This has renewed interest in therapeutic alternatives, with Xafty’s invitation seen as a clear sign of this shift.



Unlike conventional antivirals that target specific pathogens, Xafty is positioned as a first-of-its-kind universal antiviral, using a broad inhibitory mechanism to potentially combat multiple respiratory viruses. This marks the first time a broad-spectrum antiviral has been featured on an official U.S. health authority platform.

Byung-joon Bae, president of Hyundaibioscience, emphasized the milestone. “Xafty’s recognition as a potential global health security asset carries profound significance,” Bae stated. “We are committed to advancing international health security partnerships and shaping a new framework for pandemic preparedness.”